Epstein-Barr virus and multiple sclerosis: supporting causality
F Aloisi, M Salvetti - The Lancet Neurology, 2022 - thelancet.com
F Aloisi, M Salvetti
The Lancet Neurology, 2022•thelancet.com1 Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with
CJD: a double-blind study. Neurology 2004; 62: 714–18. 2 Geschwind MD, Kuo AL, Wong
KS, et al. Quinacrine treatment trial for sporadic Creutz-feldt-Jakob disease. Neurology
2013; 81: 2015–23. 3 Haïk S, Marcon G, Mallet A, et al. Doxycycline in Creutzfeldt-Jakob
disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;
13: 150–58.
CJD: a double-blind study. Neurology 2004; 62: 714–18. 2 Geschwind MD, Kuo AL, Wong
KS, et al. Quinacrine treatment trial for sporadic Creutz-feldt-Jakob disease. Neurology
2013; 81: 2015–23. 3 Haïk S, Marcon G, Mallet A, et al. Doxycycline in Creutzfeldt-Jakob
disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;
13: 150–58.
1 Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 2004; 62: 714–18. 2 Geschwind MD, Kuo AL, Wong KS, et al. Quinacrine treatment trial for sporadic Creutz-feldt-Jakob disease. Neurology 2013; 81: 2015–23. 3 Haïk S, Marcon G, Mallet A, et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014; 13: 150–58.
thelancet.com
